Objectives To describe the radiological phenotype of HER2-mutant lung cancers on CT at
presentation. Methods Eligible patients with lung adenocarcinomas with HER2 mutations …

HER2 is a major proliferative driver in lung cancer. HER2 gene aberrations impact the
prognosis of lung adenocarcinoma (ADC). A one‐step reverse transcription‐polymerase …

Introduction A fraction of lung adenocarcinomas harbor activating mutations in the HER2
kinase domain. HER2-targeted therapies have shown minimal benefit in molecularly …

Introduction HER2 oncogene is a member of the EGFR family, encoding a transmembrane
receptor that drives and regulates cell proliferation. HER2 mutations are identified in about …

Objectives While novel anti-human epidermal growth factor receptor 2 (HER2) agents have
recently been developed, no definite criteria have been proposed as indications for the use …

Background Human epidermal growth factor receptor (HER)-2 is a driver gene in non-small
cell lung cancer (NSCLC). The present study evaluated the mutation rate of HER-2 within …

Lung Cancer That Harbors a HER2 Mutation: Epidemiologic Characteristics and
Therapeutic Perspectives Page 1 Lung Cancer That Harbors a HER2 Mutation …

Background Dysregulation of HER2 signaling pathways results in tumor progression in
several types of carcinomas. The aim of the current study is to identify clinicopathological …

Background Human epidermal growth factor 2 (HER2) is a potential driver oncogene.
Although HER2-targeted precision therapy has been tested in non-small cell lung cancer …

Background Activating EGFR mutations, HER2, and HER3 are implicated in lung cancer;
however, with the exception of EGFR gene amplification in lung adenocarcinoma harboring …